IBIO - iBio, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
+0.0201 (+3.00%)
At close: 3:48PM EST
Stock chart is not supported by your current browser
Previous Close0.6700
Bid0.0000 x 800
Ask1.0100 x 800
Day's Range0.6700 - 0.7000
52 Week Range0.6000 - 3.5000
Avg. Volume124,328
Market Cap12.896M
Beta (3Y Monthly)-1.15
PE Ratio (TTM)N/A
EPS (TTM)-1.3220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting

    NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles, Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsored by Bio-Manguinhos/Fiocruz, a unit of the Brazilian Ministry of Health. “I am honored to have this opportunity to highlight the significant product flexibility, time- and cost-savings provided by iBio’s plant-based technology platform and CDMO offering to my fellow researchers and industry participants and, in so doing, help support the development of new business relationships and commercial collaborations for iBio in Brazil and internationally,” said Dr. Salgueiro.

  • GlobeNewswire2 months ago

    iBio and CC-Pharming Hold First Design and Strategy Meeting

    NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Pharming Ltd of Beijing China at iBio’s development and manufacturing facility in Bryan Texas. The meeting initiates the first stage of the companies’ business collaboration and will include work on product, process, and facility design for a monoclonal therapeutic antibody product: a plant-derived, bio-better rituximab. The companies will hold a joint press briefing at 5 p.m. on Tuesday, October 2, at the Stella Hotel, adjacent to the iBio site.

  • ACCESSWIRE6 months ago

    Free Technical Research on Nektar Therapeutics and Three More Biotech Equities

    On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN).

  • Why iBio Inc’s (NYSEMKT:IBIO) Ownership Structure Is Important
    Simply Wall St.6 months ago

    Why iBio Inc’s (NYSEMKT:IBIO) Ownership Structure Is Important

    I am going to take a deep dive into iBio Inc’s (AMEX:IBIO) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure of a companyRead More...

  • ACCESSWIRE7 months ago

    Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).

  • Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?
    Simply Wall St.8 months ago

    Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?

    After reading iBio Inc’s (AMEX:IBIO) latest earnings update (31 December 2017), I found it beneficial to look back at how the company has performed in the past and compare thisRead More...